$500.00 $450.00

Pharmacogenetics Panel covering the major drug classes and common botanicals (botanicogenomics). 



If you do not have a suitable genome analysis through a CLIA certified lab (23 and me and My Heritage DNA are acceptable direct to consumer labs) please contact NGI.  Genome kits can be purchased and de-identified through NGI for $150.


The cytochrome P450 system (CYP) is responsible for detoxifying drugs, steroid hormones and other toxic chemicals via the use of the enzymes coded by the genes listed below. Any variation in the genome will result in an improper coding for the enzyme which will compromise the enzymes crucial ability to cleanse the body of harmful toxicants. Over expression can be a problem, but more likely under expression or utilization is the problem with the majority of these enzymes. These are called “phase 1 detoxification” enzymes are generally making more dangerous metabolites in anticipation that the “phase 2 detoxification: enzymes will conjugate, or “take out the trash.”

The PharmaDx analyzes genetics in both phase 1 and phase 2 detoxification as well as other pathways that assess ones ability to metabolize medications such as statins, opioids and benzodiazepines. Knowledge of these genetic variations helps to decrease the risk of adverse drug reactions while empowering patients to make selective medication choices that help to decrease the risk of long term poly-pharmacy.

No additional testing is required for this panel.


There are no reviews yet.

Be the first to review “PharmaDx”

Your email address will not be published.